Sep 13

Eficacia y seguridad de edoxabán frente a enoxaparina para la prevención del tromboembolismo venoso después de una artroplastia total de cadera: STARS JV.

Fuente
Este artículo es originalmente publicado en:

http://www.ncbi.nlm.nih.gov/pubmed/26269694?dopt=Abstract&holding=f1000,f1000m,isrctn

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534125/

http://www.thrombosisjournal.com/content/13/1/27

http://www.healio.com/cardiology/arrhythmia-disorders/news/online/%7B2df92bb5-cabf-4181-ac0f-5d5d4eed06e7%7D/edoxaban-prevents-vte-better-than-enoxaparin-after-total-hip-arthroplasty?utm_source=maestro&utm_medium=email&utm_campaign=cardiology%20news
De:

Fuji T1, Fujita S2, Kawai Y3, Nakamura M4, Kimura T5, Fukuzawa M6, Abe K7, Tachibana S8.

Thromb J. 2015 Aug 12;13:27. doi: 10.1186/s12959-015-0057-x. eCollection 2015.
Todos los derechos reservados para:

© 2015 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.

 

Abstract

BACKGROUND:

In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and safety of edoxaban with enoxaparin for the prevention of VTE after THA in Japan.

CONCLUSIONS:

Oral edoxaban 30 mg once daily was superior to subcutaneous enoxaparin 2000 IU twice daily in the prevention of VTE followingTHA without increasing the risk for major or CRNM bleeding.

KEYWORDS:

Edoxaban; Enoxaparin; Factor Xa; Thromboprophylaxis; Total hip arthroplasty

PMID:
26269694
[PubMed]
PMCID:
PMC4534125

Free PMC Article

Deja un comentario

Your email address will not be published.

A %d blogueros les gusta esto: